Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 5Phase 3 3Phase 1/2 2

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 4Genitourinary 1

Conditions

Prostatic Neoplasms 84Breast Neoplasms 10Neoplasm Metastasis 7Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer 3Castration-resistant Prostate Cancer 3Triple Negative Breast Neoplasms 2Castration Resistant Metastatic Prostate Cancer 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostatic Diseases 1Prostate Carcinoma Metastatic to the Bone 1Prostate Adenocarcinoma 1Primary Breast Cancer ER+ve 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Progressive Castration-resistant Prostate Cancer 1Metastatic Hormone-sensitive Prostate Cancer 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × enzalutamide × Clear all
NCT03899155 2026-05-27

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT03314324 2025-04-17

ODENZA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed
250 enrolled
Tumor-Agnostic

Neoplasms

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Astellas Pharma Inc

Phase 2 Completed
60 enrolled 24 charts
Tumor-Agnostic

Neoplasms

NCT01288911 2024-12-06

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Astellas Pharma Inc

Phase 2 Completed
375 enrolled 24 charts
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01663415 2012-09-17

A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡